InvestorsHub Logo
Post# of 252499
Next 10

BTH

Followers 16
Posts 4145
Boards Moderated 1
Alias Born 06/11/2010

BTH

Re: mcbio post# 155600

Monday, 01/21/2013 11:41:24 AM

Monday, January 21, 2013 11:41:24 AM

Post# of 252499
Did you know this is being presented this week at ASCO GI?

Second-line therapy of KRAS-mutated mCRC with the MEK inhibitor selumetinib in combination with irinotecan: An AGICC study (Hochster, et al, abstract 380)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.